Angiotensin Converting Enzyme 2 News and Research

RSS

ACE2 receptors in the kidney not linked to high BP or RAS blockers

Even as the COVID-19 pandemic continues to smolder and flare up in various parts of the world, researchers are still trying to make sense of the virus, its routes of spread, its target tissues, and the immune responses it induces. One crucial piece of knowledge is that the primary viral receptor is a human enzyme called angiotensin-converting enzyme 2 (ACE2).

27 May 2020

Study shows children and adults have a comparable expression of SARS-CoV-2 entry-related genes

A recent paper by researchers from China demonstrated comparable expression levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry mediators in adults and children, suggesting that previously implied difference in viral-entry associated genes is likely not responsible for milder symptoms in children. The study is currently available on the medRxiv preprint server.

27 May 2020

Mouse model mimics clinical course and pathology observed in COVID-19 patients

A mouse model of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reproduces features observed in human patients, researchers report May 26 in the journal Cell Host & Microbe.

27 May 2020

Study shows antihypertensive drugs do not raise serum levels of ACE2

A new study published on the preprint server medRxiv* by researchers from Iceland and the U.S. shows how treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) does not raise angiotensin-converting enzyme 2 (ACE2) levels in human serum – and cautions against the discontinuation of these drugs among patients affected with coronavirus disease (COVID-19).

26 May 2020

ACE2 receptors for SARS-CoV-2 in human eye

Since its emergence in Wuhan, China, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly over most of the world’s inhabited regions, causing millions of cases and hundreds of thousands of deaths. The primary symptoms of COVID-19, the disease caused by SARS-CoV-2, are fever, dry cough, and tiredness.

25 May 2020

The infection of lung stem cells may determine SARS-CoV-2 pathogenicity

A group of researchers from Russia and France has demonstrated how stem cells in the lungs can be readily infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading to significant defects in their regeneration capacity and more severe coronavirus disease (COVID-19). Their manuscript is currently available on the preprint server bioRxiv.

25 May 2020

SARS-CoV-2 is uniquely adapted to infect humans

The novel coronavirus pandemic has sparked much debate on its origin, with some suggesting it may have been laboratory-grown. Previous studies, however, mentioned that it is zoonotic in nature, which means that the virus jumped from wild animals and found its way to humans.

25 May 2020

Heparin may stop SARS-CoV-2 infecting host cells

Researchers at the University of Sheffield have developed a new assay that can be used to assess the attachment of viruses to host cells and to test potential inhibitors of viral infection.

24 May 2020

New biomarkers to consider for SARS-CoV-2 vaccine

Researchers at the University of Melbourne have made new discoveries about how the immune system responds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could be important to consider in vaccine research.

24 May 2020

RAAS inhibitors are safe to use in COVID-19 patients, study shows

The coronavirus disease (COVID-19) is a novel illness that has spread across the globe in just five months. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral infection binds to the angiotensin-converting enzyme 2 (ACE2) to enter and invade cells.

21 May 2020

Excessive blood clotting and stroke in COVID-19 patients

The coronavirus disease COVID-19 is causing excessive blood clotting and stroke in young and healthy people, a new study has found.

21 May 2020

Nasopharyngeal swab vs. saliva for COVID-19 diagnosis

One thing has become apparent in the ongoing pandemic of COVID-19. Early diagnosis and treatment, when necessary, is crucial to prevent the progression of the disease to critical and life-threatening stages where the mortality rate is much higher than otherwise. Rapid diagnosis is also key to containing outbreaks by allowing for efficient contact tracing in hospitals as well as in communities.

21 May 2020

Main receptors used by SARS-CoV-2 for cell entry are absent in the human placenta

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unlikely to infect human placenta through the canonical cell entry mediators, Wayne State University researchers showed that other interacting proteins may still play an important role during the viral infection. The study is currently available on the preprint server bioRxiv.

20 May 2020

Sleep apnea may increase the risk of severe COVID-19, say researchers

An analysis conducted by researchers at the University of Turku and Turku University Hospital in Finland has suggested that obstructive sleep apnea (OSA) may be a risk factor for severe coronavirus disease 2019 (COVID-2019).

19 May 2020

No SARS-COV-2 among young children in Belgium attending daycare, report researchers

A study conducted by researchers in Belgium has found no evidence to support concerns that asymptomatic young children may be a source of severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) transmission.

19 May 2020

Smoking increases ACE2 protein in the lungs which may promote COVID-19 infection

Previous data from COVID-19 patients suggests that cigarette smokers are more likely to have health complications.

18 May 2020

Human immune repertoire may not commonly produce cross-neutralizing antibodies to coronaviruses

Patients infected with either severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 produce antibodies that bind to the other coronavirus, but the cross-reactive antibodies are not cross protective, at least in cell-culture experiments, researchers report May 17 in the journal Cell Reports.

18 May 2020

Potential new treatment approach to fatal COVID-19

Researchers from the University of Colorado Anschutz Medical Campus and Pathways Bioscience in the United States have found that activating a transcription factor involved in oxidative stress regulation, antiviral activity, and inflammation may serve as a new treatment approach to coronavirus disease 2019 (COVID-19).

18 May 2020

Cigarette smoke spurs the lungs to make more SARS-CoV-2 receptors

New research from CSHL scientists suggests that cigarette smoke spurs the lungs to make more ACE2 (angiotensin-converting enzyme 2), the protein that the coronavirus responsible for COVID-19 grabs and uses to enter human cells.

18 May 2020

New and unexplored angle in the binding of SARS-CoV-2 to host cells

Researchers in the Netherlands, Cuba, and Italy have made important discoveries about the carbohydrate-mediated binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to host cell lectin receptors and host lung microbiota.

17 May 2020